Charles Schwab Investment Management Inc. bought a new position in shares of MBX Biosciences, Inc. (NYSE:MBX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 93,311 shares of the company's stock, valued at approximately $1,720,000. Charles Schwab Investment Management Inc. owned approximately 0.28% of MBX Biosciences as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also recently bought and sold shares of the stock. Rhumbline Advisers bought a new stake in shares of MBX Biosciences in the fourth quarter valued at about $175,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in MBX Biosciences in the 3rd quarter valued at approximately $278,000. Point72 Asset Management L.P. bought a new stake in MBX Biosciences in the 3rd quarter valued at approximately $405,000. Barclays PLC acquired a new position in MBX Biosciences during the 3rd quarter worth approximately $426,000. Finally, Geode Capital Management LLC bought a new position in shares of MBX Biosciences during the 3rd quarter worth approximately $579,000.
Insiders Place Their Bets
In related news, CEO P. Kent Hawryluk purchased 50,000 shares of the firm's stock in a transaction on Tuesday, February 4th. The stock was purchased at an average cost of $10.69 per share, for a total transaction of $534,500.00. Following the completion of the purchase, the chief executive officer now directly owns 448,277 shares in the company, valued at $4,792,081.13. This trade represents a 12.55 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Carl L. Gordon purchased 47,502 shares of the stock in a transaction on Friday, February 14th. The shares were bought at an average cost of $9.87 per share, for a total transaction of $468,844.74. Following the transaction, the director now directly owns 3,205,930 shares in the company, valued at approximately $31,642,529.10. The trade was a 1.50 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 240,672 shares of company stock valued at $2,555,308 in the last three months.
MBX Biosciences Stock Performance
Shares of MBX stock traded up $0.11 during trading on Wednesday, reaching $6.97. The company's stock had a trading volume of 268,542 shares, compared to its average volume of 232,118. MBX Biosciences, Inc. has a one year low of $6.67 and a one year high of $27.50. The business has a fifty day moving average price of $9.70 and a 200-day moving average price of $16.42.
About MBX Biosciences
(
Free Report)
MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.
Featured Articles
Before you consider MBX Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MBX Biosciences wasn't on the list.
While MBX Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
